RxDoctor Payments Data

Brandon Cutler, DO

Medical Oncology · Kettering, OHNPI 1356464614

Payments from drug & device makers

$897in general payments, 2019–2025

Across 8 payments — averaging $112.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$350
  • Novocure GmbH$200
  • Lilly USA, LLC$197
  • Johnson & Johnson$100
  • Regeneron Healthcare Solutions, Inc.$17
  • Genentech USA, Inc.$17
  • plus $17 from 1 others

What the payments were for

  • Speaking & faculty fees$20022%
  • Grants$35039%
  • Food & beverage$172%
  • Education$33037%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$897 in reported general payments places this provider in the 20th percentile of 157 medical oncology providers in Ohio.

See all medical oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$123,718
Medicare patients
303
Services billed
1,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide54$766,478
RevlimidLenalidomide36$712,241
CalquenceAcalabrutinib Maleate26$402,609
FotivdaTivozanib Hcl11$340,934
ImbruvicaIbrutinib21$333,417
ErleadaApalutamide19$272,520
TasignaNilotinib Hcl13$248,709
Lenalidomide18$245,412
BraftoviEncorafenib11$178,483
MektoviBinimetinib11$175,116
EliquisApixaban141$104,253
XareltoRivaroxaban53$44,603
Abiraterone Acetate14$38,694
Ondansetron Hcl82$1,913
Anastrozole44$885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$350$402,60926 claims
Johnson & JohnsonErleada, Xarelto$100$317,12372 claims
Lilly USA, LLCOlanzapine$197$15019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 157 medical oncology providers in Ohio.

Other medical oncology in Kettering

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →